Type your tag names separated by a space and hit enter

    [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients].

    Abstract

    The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated.

    METHOD

    open, non-controlled surveillance study conducted at 744 centers.

    PATIENTS

    3,076 patients suffering from bronchitis.

    MEDICATION

    600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose.

    END POINTS

    evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance.

    RESULTS

    impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%).

    CONCLUSIONS

    treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.

    Authors+Show Affiliations

    Gerards HH
    ,

    Inpharzam GmbH, Gräfelfing.

    Vits U

    Source

    Fortschritte der Medizin 109:34 1991 Nov 30 pg 707-10

    MeSH

    Acetylcysteine
    Administration, Oral
    Bronchitis
    Drug Administration Schedule
    Female
    Humans
    Male
    Middle Aged
    Pilot Projects

    Pub Type(s)

    English Abstract
    Journal Article

    Language

    ger

    PubMed ID

    1765342

    Citation

    Gerards, H H., and U Vits. "[Therapy of Bronchitis. Successful Single-dosage Treatment With N-acetylcysteine, Results of an Administration Surveillance Study in 3,076 Patients]." Fortschritte Der Medizin, vol. 109, no. 34, 1991, pp. 707-10.
    Gerards HH, Vits U. [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. Fortschr Med. 1991;109(34):707-10.
    Gerards, H. H., & Vits, U. (1991). [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. Fortschritte Der Medizin, 109(34), pp. 707-10.
    Gerards HH, Vits U. [Therapy of Bronchitis. Successful Single-dosage Treatment With N-acetylcysteine, Results of an Administration Surveillance Study in 3,076 Patients]. Fortschr Med. 1991 Nov 30;109(34):707-10. PubMed PMID: 1765342.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. AU - Gerards,H H, AU - Vits,U, PY - 1991/11/30/pubmed PY - 1991/11/30/medline PY - 1991/11/30/entrez SP - 707 EP - 10 JF - Fortschritte der Medizin JO - Fortschr. Med. VL - 109 IS - 34 N2 - UNLABELLED: The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated. METHOD: open, non-controlled surveillance study conducted at 744 centers. PATIENTS: 3,076 patients suffering from bronchitis. MEDICATION: 600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose. END POINTS: evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance. RESULTS: impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%). CONCLUSIONS: treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated. SN - 0015-8178 UR - https://www.unboundmedicine.com/medline/citation/1765342/ L2 - https://medlineplus.gov/acutebronchitis.html DB - PRIME DP - Unbound Medicine ER -